A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission

Trial Profile

A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Cancer vaccine MUC-1 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Immutep Limited; Prima BioMed
  • Most Recent Events

    • 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
    • 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 21 May 2015 Results of overall survival analysis in second remission patients published in a Prima BioMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top